|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AIPL1 |
Gene summary for AIPL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AIPL1 | Gene ID | 23746 |
| Gene name | aryl hydrocarbon receptor interacting protein like 1 | |
| Gene Alias | AIPL2 | |
| Cytomap | 17p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000413 | UniProtAcc | F1T0B6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23746 | AIPL1 | HCC1 | Human | Liver | HCC | 4.22e-13 | 1.02e+00 | 0.5336 |
| 23746 | AIPL1 | HCC2 | Human | Liver | HCC | 2.34e-21 | 1.34e+00 | 0.5341 |
| 23746 | AIPL1 | HCC5 | Human | Liver | HCC | 1.52e-13 | 1.09e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007121421 | Liver | HCC | cellular response to abiotic stimulus | 183/7958 | 331/18723 | 1.59e-06 | 2.26e-05 | 183 |
| GO:010400421 | Liver | HCC | cellular response to environmental stimulus | 183/7958 | 331/18723 | 1.59e-06 | 2.26e-05 | 183 |
| GO:001820811 | Liver | HCC | peptidyl-proline modification | 42/7958 | 58/18723 | 3.73e-06 | 4.85e-05 | 42 |
| GO:00004131 | Liver | HCC | protein peptidyl-prolyl isomerization | 31/7958 | 42/18723 | 3.83e-05 | 3.80e-04 | 31 |
| GO:00714782 | Liver | HCC | cellular response to radiation | 104/7958 | 186/18723 | 1.48e-04 | 1.19e-03 | 104 |
| GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AIPL1 | SNV | Missense_Mutation | novel | c.1107N>C | p.Glu369Asp | p.E369D | Q9NZN9 | protein_coding | tolerated_low_confidence(0.49) | benign(0.01) | TCGA-A2-A1FX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| AIPL1 | SNV | Missense_Mutation | c.230N>T | p.Thr77Ile | p.T77I | Q9NZN9 | protein_coding | tolerated(0.15) | benign(0.139) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
| AIPL1 | SNV | Missense_Mutation | c.210N>T | p.Glu70Asp | p.E70D | Q9NZN9 | protein_coding | tolerated(0.12) | benign(0.101) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| AIPL1 | SNV | Missense_Mutation | novel | c.1107N>C | p.Glu369Asp | p.E369D | Q9NZN9 | protein_coding | tolerated_low_confidence(0.49) | benign(0.01) | TCGA-E9-A1NG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
| AIPL1 | SNV | Missense_Mutation | rs146153236 | c.562N>T | p.Leu188Phe | p.L188F | Q9NZN9 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-Q1-A5R1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| AIPL1 | SNV | Missense_Mutation | rs145112457 | c.88N>A | p.Gly30Arg | p.G30R | Q9NZN9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| AIPL1 | SNV | Missense_Mutation | rs145112457 | c.88N>A | p.Gly30Arg | p.G30R | Q9NZN9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3861-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| AIPL1 | SNV | Missense_Mutation | novel | c.973A>G | p.Asn325Asp | p.N325D | Q9NZN9 | protein_coding | tolerated(0.11) | benign(0.013) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| AIPL1 | SNV | Missense_Mutation | rs759934433 | c.113N>A | p.Arg38His | p.R38H | Q9NZN9 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| AIPL1 | SNV | Missense_Mutation | c.1030N>A | p.Ala344Thr | p.A344T | Q9NZN9 | protein_coding | tolerated_low_confidence(0.23) | benign(0.006) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |